A2M and B-cell chronic lymphocytic leukemia: A2M also participates, with IgG molecules, in formation of immune complexes that generate aggregated/hexameric structures (A2M-IgG-hexamers) and activate the classical pathway (CP) of the complement system in patients with Chronic Lymphocytic Leukemia (CLL) (4).